The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: An important determinant of outcome

Journal of Critical Care

Volumn 27, Issue 3, 2012, Pages 322.e7-322.e14

  Muscedere, John G ^a,b   Shorr, Andrew F ^c   Jiang, Xuran ^b   Day, Andrew ^b   Heyland, Daren K ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Adequacy of therapy; Antibiotics; Clinical outcomes; Ventilator associated pneumonia

Indexed keywords

CIPROFLOXACIN; MEROPENEM;

ADEQUATE THERAPY; ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; STENOTROPHOMONAS; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84861187338     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2011.09.004     Document Type: Article

References (31)

1. Edwards J., Peterson K., Andrus M., et al. and the National Healthcare Safety Network Facilities: National Healthcare Safety Network (NHSN) Report, data summary for 2006 through 2007, issued November 2008. Am J Infect Control 2008, 36:609-626.
2. Safdar N., Dezfulian C., Collard H.R., et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005, 33:2184-2193.
3. Muscedere J., Martin C.M., Heyland D.K. The impact of ventilator associated pneumonia on the Canadian health care system. J Crit Care 2008, 23:5-10.
4. Baker A.M., Meredith J.W., Chang M., et al. Bronchoscopically guided management of ventilator-associated pneumonia in trauma patients. J Bronchology 2003, 10:7-16.
5. American Thoracic Society Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
6. Muscedere J., Dodek P., Keenan S., et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care 2008, 23:138-147. for the VAP Guidelines Committee and the Canadian Critical Care Trials Group.
7. Kuti E., Patel A., Coleman C. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 2008, 23:91-100.
8. Kollef M. Treatment of ventilator-associated pneumonia: get it right from the start. Crit Care Med 2003, 31:969-970.
9. Dalhoff A., Ambrose P., Mouton J. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 2009, 37:296-305.
10. Heyland D.K., Dodek P., Day A., et al. A randomized trial of diagnostic techniques for suspected ventilator-associated pneumonia. New Eng J Med 2006, 355:2619-2630. for the Canadian Critical Care Trials Group.
11. Heyland D.K., Dodek P., Muscedere J., et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36:737-744. for the Canadian Critical Care Trials Group.
12. Knaus W., Draper E., Wagner D., Zimmerman J. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
13. Marshall J., Cook D., Christou N., et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995, 23:1638-1652.
14. Pugin J., Auckenthaler R., Mili N., et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991, 143:1121-1129.
15. Hosmer D.J., Lemeshow S. Applied logistic regression 1989, John Wiley and Sons, New York, NY.
16. Heyland D.K., Cook D.J., Griffith L., et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient for the Canadian Critical Care Trials Group. Am J Respir Crit Care Med 1999, 159:1249-1256.
17. MacArthur R., Miller M., Albertson T., et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004, 38:284-288.
18. Garnacho-Montero J., Garcia-Garmendia J., Barrero-Almodovar A., et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31:2751.
19. Kollef M., Sherman G., Ward S., Fraser V. Inadequate antimicrobial treatment of infections. Chest 1999, 115:462-474.
20. Køster-Rasmussen R., Korshin A., Meyer C. Antibiotic treatment delay and outcome in acute bacterial meningitis. J Infect 2008, 57:449-454.
21. Kumar A., Roberts D., Wood K., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
22. Blot S., Depuydt P., Vogelaers D. Maximizing rates of empiric appropriate antibiotic therapy with minimized use of broad-spectrum agents: are surveillance cultures the key?. Intensive Care Med 2008, 34:2130-2133.
23. Muscedere J. Ventilator associated pneumonia and mortality: the controversy continues. Crit Care Med 2009, 37:2845-2846.
24. Muscedere J., Day A., Heyland D.K. Mortality, attributable mortality and clinical events as endpoints for clinical trials of ventilator-associated pneumonia and hospital-acquired Pneumonia. Clin Infect Dis. 2010, 51(Suppl 1):S120-S125.
25. Melsen W., Rovers M., Bonten M. Ventilator associated pneumonia and mortality: a systematic review of observational studies. Crit Care Med 2009, 37:2709-2718.
26. Rusnak M., Drake T., Hackbarth C., Sande M. Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs. J Infect Dis 1984, 149:980-985.
27. Johnson D., Thompson B. Efficacy of single-agent therapy with azlocillin, ticarcillin, amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. Am J Med 1986, 80:53-58.
28. Safdar N., Handelsman J., Maki D.G. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4:519-527.
29. Paul M., Benuri-Silbiger I., Soares-Weiser K., Leibovici L. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004, 328:668.
30. Garnacho-Montero J., Sa-Borges M., Sole-Violan J., et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007, 35:1888-1895.
31. Parker C., Kutsogiannis J., Muscedere J., et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 2008, 23:18-26. for the Canadian Critical Care Trials Group.